Rare Diseases Recent News
Ultragenyx Discontinues Phase 3 GNE Myopathy Study
Retrophin Up 40% On Kidney Disease Drug Trial, Shkreli Still Wants His $25+ Million 'Hogan Reward'
Ultragenyx Pharmaceutical Spikes 4% Following Release Of Positive Phase 2 Data
Sanofi Is Looking For Rare Disease Acquisitions, FT Says
BioCryst Pharmaceuticals Is Plummeting 65%
Is Shire's $34 Billion Baxalta Acquisition Good For Shareholders? Most Think So